Abstract:The most common cause of chronic liver disease throughout the world is nonalcoholic fatty liver disease (NAFLD), which is also characterized by liver fibrosis and inflammation and leads to cirrhosis with progression to hepatic carcinoma in some cases. [ 1 ] NAFLD is a chronic disorder of dysmetabolic syndrome. [ 2 , 3 ] Most cases of NAFLD are characterized by imbalanced glucose levels, obesity, hypertension, hyperlipidemia, and hepatic expression disorders. [ 4 ] This disease affects more than half of the world's population with obesity and diabetes. [ 5 ] The conditions included low-density and high-density lipoprotein, total cholesterol, and hypertriglyceridemia. It has been reported that NAFLD is a presumed cause of chronic liver inflammation in Asian and Western countries. [ 6 ] The prevalence rate of NAFLD is 5% to 30%. However, in the world population, a global survey revealed that Pakistan and India are the countries with the most prevalent type 2 diabetes mellitus (T2DM) and obesity. [ 6 , 7 ] Furthermore, NAFLD incidence is very high among individuals with T2DM, and NAFLD incidence is expected to increase further. T2DM and NAFLD are frequently encountered in general practice. Given the complexity of their management, a multidisciplinary approach is often required, incorporating the expertise of gastroenterologists, diabetologists, and internists. This integrated care model is essential for addressing the multifaceted nature of these conditions. [ 8 ] T2DM and NAFLD are both highly prevalent in primary care, with T2DM affecting over 422 million people globally [ 9 ] and NAFLD affecting 25% to 30% of the general population. [ 9 , 10 ] The conditions are closely linked, especially through insulin resistance, with up to 70% of T2DM patients also having NAFLD. [ 10 ] This coexistence significantly increases the risk of cardiovascular disease and liver complications. [ 11 ] Primary care physicians play a critical role in the early detection and management of both conditions, which requires a multidisciplinary approach involving specialists in diabetology, gastroenterology, and internal medicine. [ 12 ] Effective management focuses on lifestyle changes, pharmacological treatments, and regular monitoring to prevent the progression of these chronic diseases. [ 13 ] Nonalcoholic steatohepatitis (NASH) is a destructive disorder of NAFLD characterized by inflammation, hepatic necrosis, and late fibrosis and may further progress to a crucial form of cirrhosis. [ 14 , 15 ] The early transience rate among NASH patients involves hepatocellular carcinoma and liver cirrhosis, along with extrahepatic manifestations, mostly cardiac disease. [ 3 , 16 , 17 ] The pathogenesis of NAFLD involves multiple factors, including an excessively imbalanced diet and fat-rich food ingestion, along with impaired insulin sensitivity and oxidative stress-induced damage. [ 18 ] However, persistent cellular stress and insulin insensitivity may lead to hepatic steatosis, which causes NAFLD and progression to NASH. [ 19 ] Recent evidence suggested that a sodium-glucose cotransporter 2 (SGLT2) inhibitor improved NAFLD in patients with T2DM. [ 20 ] Ertugliflozin is the newest SGLT2 inhibitor used in patients for the treatment of T2DM. It accelerates urinary glucose excretion, causing a decrease in blood glucose levels, osmotic urination and loss of calories. [ 20 , 21 ] Ertugliflozin improves glucose imbalance and beta cell function, and its effect on insulin sensitivity also decreases body mass. [ 22 ] A decrease in insulin insensitivity caused by canagliflozin treatment is very effective in all patients suffering from NAFLD. [ 23 , 24 ] Recently, established studies have shown that SGLT2 inhibitors considerably decrease body weight and body mass index in human trials. [ 20 </sup -Abstract Truncated-

Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats

Tofogliflozin attenuates renal lipid deposition and inflammation via PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Abstract 16307: Tofogliflozin Improves Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction Mice

Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction

Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis

Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes

Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways

Restoration of Sinusoid Fenestrae followed by Targeted Nanoassembly Delivery of an Anti‐Fibrotic Agent Improves Treatment Efficacy in Liver Fibrosis

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease

The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial

Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice

Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy via the TGF-β1/Smad pathway: implications for liver cancer

Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: A retrospective study

Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis

Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor "canagliflozin" on the hepatic damage triggered by hypertension in rats

TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways